Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GEB - Genetronics Biomedical -- Ignore unavailable to you. Want to Upgrade?

To: Dan Hamilton who wrote (21)	8/2/2000 10:33:40 AM
From: Alfred W. Post	Respond to of 31

Thats exactly what I answered and if I get additional news I will bring it. Fred

To: Dan Hamilton who wrote (21)	8/3/2000 2:22:25 AM
From: Alfred W. Post	Read Replies (1) \| Respond to of 31

Here is the second answer of GEB Ethicon Endo-Surgery, in its phone call to us, simply invoked a clause in the contract to terminate our relationship . They did not give us any reason for this decision, nor did they answer us when directly asked them for a reason. Since we do not know we cannot tell you. In a Dow Jones news story about this, Ethicon declined to comment because they said they don't discuss their business decisions in public. You are, of course, free to call Ethicon yourself. I would urge you to listen to Martin Nash's discussion of Genetronics' direction for the future minus Ethicon. In the United States, dial 1-800-475-6701 and use the program access code 531364. If you are in Switzerland, dial 320 365 3844 and use the program access code 531364. +++++++++++++++++++++++++ Clarke L. Galvin Investor Relations Manager Genetronics, Inc. 858.410.3104 858.410.3395 fax ir@genetronics.com +++++++++++++++++++++++++ This email contains certain forward-looking statements relating to the Company's plans to develop its electroporation drug delivery system, and its corporate partnering activities. The availability of resources to support operations and plans for obtaining additional financing cannot be assured. Actual events or results may differ from the Company's expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, and capital market conditions, and others set forth in the Genetronics Annual Report, on Form 10-K and other regulatory filings. There can be no assurance that any product in Genetronics product pipeline will be successfully developed or manufactured, or that final results of human pilot studies or clinical studies will be supportive of regulatory approvals required to market products. The American and Toronto Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of this email. >>> "Alfred W. Post" <alfred.post@datazug.ch> 8/2/00 12:07:51 AM >>> Thanks for your E-mail. Wnile J&J apparently had the right to terminate without cause, I feel you also have the right to ask for the reason and that is what I would like to know. Don't tell me you did not ask or do not know the reason why. As we have invested heavely into GEB and advised clients to do the same, we feel to have the right to now know what went or what is wrong. Please let us know. thanks yours Alfred W. Post